Work

Gene–Diet Interactions Within the FADS Cluster Modulate n-3 PUFA Profiles in Postmenopausal Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy: A Randomized Controlled Trial

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Background/Objectives: Aromatase inhibitors (AIs), standard adjuvant treatment for hormone-receptor-positive (HR+) breast cancer (BRC), reduce recurrence risk but frequently induce metabolic side effects. Responses to n-3 long-chain polyunsaturated fatty acids (LC-PUFAs) interventions vary between individuals, potentially driven by fatty acid desaturase (FADS) gene variants. This study aimed to evaluate whether FADS polymorphisms (rs174537, rs174576, rs174602) modulate plasma PUFA responses to nutritional intervention in BRC survivors on AIs. Methods: In a 16 week, parallel, three-arm, randomized, controlled trial (NCT06214598), 81 postmenopausal BRC survivors on AIs were assigned via stratified block randomization (1:1:1) to (1) anti-inflammatory diet, (2) fish oil + evening primrose oil supplementation, or (3) placebo, and 69 completed the study. Genotyping was performed using real-time PCR. Plasma fatty acids were analyzed by gas chromatography. Group × Time × Genotype interactions were tested by linear mixed-effects models (REML, unstructured covariance; n = 69; 24 tests adjusted for multiplicity (Bonferroni). Results: Supplementation significantly increased plasma eicosapentaenoic (EPA) and docosapentaenoic (DPA) acids (p < 0.001). Significant gene–diet interactions were identified: EPA increase was more pronounced in minor allele carriers of rs174537 than in major allele homozygotes (three-way interaction p = 0.011). Both EPA and DPA increased strictly among minor allele carriers of rs174576 (p < 0.001, three-way interaction p = 0.037 and p = 0.003 for EPA and DPA respectively). No genotype-dependent response was observed for rs174602, the diet, or n-6 PUFAs. Conclusions: Functional FADS variants (rs174537 and rs174576) modulate plasma n-3 PUFA responsiveness to supplementation in BRC survivors on AI therapy providing a rationale for nutrigenetic stratification in supportive cancer care.
Source: Nutrients
Language: English
Field: Nursing
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7235711714
FWCI:
Cites: 41
Cited by:
Related to: 10